OpGen (NASDAQ: OPGN) is one of 186 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare OpGen to similar businesses based on the strength of its profitability, institutional ownership, dividends, risk, valuation, analyst recommendations and earnings.
Earnings and Valuation
This table compares OpGen and its competitors gross revenue, earnings per share and valuation.
OpGen’s competitors have higher revenue, but lower earnings than OpGen. OpGen is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
11.8% of OpGen shares are owned by institutional investors. Comparatively, 49.5% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 17.4% of OpGen shares are owned by company insiders. Comparatively, 14.8% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares OpGen and its competitors’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
This is a summary of recent recommendations for OpGen and its competitors, as provided by MarketBeat.com.
||Strong Buy Ratings
OpGen currently has a consensus target price of $1.00, indicating a potential upside of 426.32%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 12.02%. Given OpGen’s stronger consensus rating and higher probable upside, equities research analysts clearly believe OpGen is more favorable than its competitors.
OpGen beats its competitors on 7 of the 12 factors compared.
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name.
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.